120 related articles for article (PubMed ID: 38501576)
1. Small-molecule inhibitor HI-TOPK-032 improves NK-92MI cell infiltration into ovarian tumours.
Deng M; Yang R; Sun Q; Zhang J; Miao J
Basic Clin Pharmacol Toxicol; 2024 May; 134(5):629-642. PubMed ID: 38501576
[TBL] [Abstract][Full Text] [Related]
2. Mitotic kinase PBK/TOPK as a therapeutic target for adult T‑cell leukemia/lymphoma.
Ishikawa C; Senba M; Mori N
Int J Oncol; 2018 Aug; 53(2):801-814. PubMed ID: 29901068
[TBL] [Abstract][Full Text] [Related]
3. PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas.
Zhu K; Cheng X; Wang S; Zhang H; Zhang Y; Wang X; Chen Y; Wu J
Front Endocrinol (Lausanne); 2021; 12():706909. PubMed ID: 35126305
[TBL] [Abstract][Full Text] [Related]
4. Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo.
Joel M; Mughal AA; Grieg Z; Murrell W; Palmero S; Mikkelsen B; Fjerdingstad HB; Sandberg CJ; Behnan J; Glover JC; Langmoen IA; Stangeland B
Mol Cancer; 2015 Jun; 14():121. PubMed ID: 26081429
[TBL] [Abstract][Full Text] [Related]
5. Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth.
Kim DJ; Li Y; Reddy K; Lee MH; Kim MO; Cho YY; Lee SY; Kim JE; Bode AM; Dong Z
Cancer Res; 2012 Jun; 72(12):3060-8. PubMed ID: 22523035
[TBL] [Abstract][Full Text] [Related]
6. NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer.
Li J; Hu H; Lian H; Yang S; Liu M; He J; Cao B; Chen D; Hu Y; Zhi C; Shen Y; Ye X; He B; Zhao M; Fan W; Xu L; Leidner R; Wu Q; Yang L; Zhang Z
Int J Biol Sci; 2024; 20(5):1578-1601. PubMed ID: 38481806
[No Abstract] [Full Text] [Related]
7. Focused Ultrasound Improves NK-92MI Cells Infiltration Into Tumors.
Yang C; Du M; Yan F; Chen Z
Front Pharmacol; 2019; 10():326. PubMed ID: 31057396
[TBL] [Abstract][Full Text] [Related]
8. PBK/TOPK mediates promyelocyte proliferation via Nrf2-regulated cell cycle progression and apoptosis.
Liu Y; Liu H; Cao H; Song B; Zhang W; Zhang W
Oncol Rep; 2015 Dec; 34(6):3288-96. PubMed ID: 26503118
[TBL] [Abstract][Full Text] [Related]
9. Cytoplasmic, nuclear, and total PBK/TOPK expression is associated with prognosis in colorectal cancer patients: A retrospective analysis based on immunohistochemistry stain of tissue microarrays.
Su TC; Chen CY; Tsai WC; Hsu HT; Yen HH; Sung WW; Chen CJ
PLoS One; 2018; 13(10):e0204866. PubMed ID: 30286126
[TBL] [Abstract][Full Text] [Related]
10. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells.
Jiang H; Zhang W; Shang P; Zhang H; Fu W; Ye F; Zeng T; Huang H; Zhang X; Sun W; Man-Yuen Sze D; Yi Q; Hou J
Mol Oncol; 2014 Mar; 8(2):297-310. PubMed ID: 24388357
[TBL] [Abstract][Full Text] [Related]
11. PBK/TOPK Is a Favorable Prognostic Biomarker Correlated with Antitumor Immunity in Colon Cancers.
Lee DH; Jeong YJ; Won JY; Sim HI; Park Y; Jin HS
Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203508
[TBL] [Abstract][Full Text] [Related]
12. PBK/TOPK expression correlates with mutant p53 and affects patients' prognosis and cell proliferation and viability in lung adenocarcinoma.
Lei B; Qi W; Zhao Y; Li Y; Liu S; Xu X; Zhi C; Wan L; Shen H
Hum Pathol; 2015 Feb; 46(2):217-24. PubMed ID: 25466965
[TBL] [Abstract][Full Text] [Related]
13. The TOPK Inhibitor HI-TOPK-032 Enhances CAR T-cell Therapy of Hepatocellular Carcinoma by Upregulating Memory T Cells.
Zhang Q; Zheng F; Chen Y; Liang CL; Liu H; Qiu F; Liu Y; Huang H; Lu W; Dai Z
Cancer Immunol Res; 2024 May; 12(5):631-643. PubMed ID: 38407902
[TBL] [Abstract][Full Text] [Related]
14. PBK/TOPK expression in non-small-cell lung cancer: its correlation and prognostic significance with Ki67 and p53 expression.
Lei B; Liu S; Qi W; Zhao Y; Li Y; Lin N; Xu X; Zhi C; Mei J; Yan Z; Wan L; Shen H
Histopathology; 2013 Nov; 63(5):696-703. PubMed ID: 24025073
[TBL] [Abstract][Full Text] [Related]
15. Gossypetin Inhibits Solar-UV Induced Cutaneous Basal Cell Carcinoma Through Direct Inhibiting PBK/TOPK Protein Kinase.
Wang L; Zhang Z; Ge R; Zhang J; Liu W; Mou K; Lv S; Mu X
Anticancer Agents Med Chem; 2019; 19(8):1029-1036. PubMed ID: 30827262
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of PBK/TOPK relates to tumour malignant potential and poor outcome of gastric carcinoma.
Ohashi T; Komatsu S; Ichikawa D; Miyamae M; Okajima W; Imamura T; Kiuchi J; Kosuga T; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Otsuji E
Br J Cancer; 2017 Jan; 116(2):218-226. PubMed ID: 27898655
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells.
Shiozawa M; Chang CH; Huang YC; Chen YC; Chi MS; Hao HC; Chang YC; Takeda S; Chi KH; Wang YS
BMC Immunol; 2018 Aug; 19(1):27. PubMed ID: 30075754
[TBL] [Abstract][Full Text] [Related]
18. PDZ binding kinase (PBK) is a theranostic target for nasopharyngeal carcinoma: driving tumor growth via ROS signaling and correlating with patient survival.
Wang MY; Lin ZR; Cao Y; Zheng LS; Peng LX; Sun R; Meng DF; Xie P; Yang JP; Cao L; Xu L; Huang BJ; Qian CN
Oncotarget; 2016 May; 7(18):26604-16. PubMed ID: 27049917
[TBL] [Abstract][Full Text] [Related]
19. PBK/TOPK, a proliferating neural progenitor-specific mitogen-activated protein kinase kinase.
Dougherty JD; Garcia AD; Nakano I; Livingstone M; Norris B; Polakiewicz R; Wexler EM; Sofroniew MV; Kornblum HI; Geschwind DH
J Neurosci; 2005 Nov; 25(46):10773-85. PubMed ID: 16291951
[TBL] [Abstract][Full Text] [Related]
20. PBK/TOPK in the differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma and its involvement in prognosis of human cholangiocarcinoma.
He F; Yan Q; Fan L; Liu Y; Cui J; Wang J; Wang L; Wang Y; Wang Z; Guo Y; Huang G
Hum Pathol; 2010 Mar; 41(3):415-24. PubMed ID: 19954816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
